PUBLISHER: The Insight Partners | PRODUCT CODE: 2086984
PUBLISHER: The Insight Partners | PRODUCT CODE: 2086984
The Asia Pacific Veterinary Vaccines Market is projected to experience significant growth, with an expected market size of approximately US$ 4,520.4 million by 2031, up from US$ 2,556.7 million in 2024. This growth translates to a compound annual growth rate (CAGR) of 8.5% from 2025 to 2031.
Executive Summary and Market Analysis
The veterinary vaccines market in the Asia Pacific region is categorized into several segments, including key countries such as China, Japan, India, Australia, South Korea, and other nations in the region. The market is anticipated to grow considerably during the forecast period, driven by robust government support and proactive initiatives from market players aimed at enhancing animal health management. Countries like Australia, India, and South Korea are identified as having substantial growth potential due to advancements in vaccine development, improvements in veterinary healthcare infrastructure, and increasing livestock populations.
Governments across the Asia Pacific are implementing policies to promote the widespread adoption of veterinary vaccination programs, which are crucial for controlling infectious and zoonotic diseases affecting animals. The rising incidence of chronic zoonotic infections that impact both animals and humans is further fueling the demand for effective veterinary vaccines. Additionally, growing awareness regarding animal welfare and disease prevention is expected to enhance the outlook for the Asia Pacific veterinary vaccines market, positioning the region as a significant growth area in the global veterinary vaccine landscape.
Strategic Insights
Market Segmentation Analysis
The Asia Pacific Veterinary Vaccines Market is segmented based on various criteria:
Market Outlook
The expansion of manufacturing plants represents a significant growth opportunity for the veterinary vaccines market. This expansion addresses critical issues such as production scalability, cost reduction, and improved accessibility of vaccines in the region. The increasing demand for veterinary vaccines, driven by rising pet ownership, livestock management needs, and international disease prevention initiatives, has prompted producers to invest in new facilities and upgrade existing ones to enhance production capacity.
For instance, in March 2024, Zoetis announced the acquisition of a 21-acre production facility in Melbourne to expand its operations and increase future capacity for developing vaccines for various animals, including sheep, cattle, dogs, cats, and horses. Similarly, in December 2023, Indian Immunologicals Limited (IIL) began constructing a new veterinary vaccine manufacturing facility in Genome Valley, Hyderabad, with an investment of Rs.700 crore (approximately US$ 82.74 million). This facility aims to produce the Foot and Mouth Disease vaccine and a combination vaccine for Foot and Mouth Disease and Haemorrhagic Septicaemia, creating over 750 jobs.
In 2024, Vaksindo Vietnam Co Ltd inaugurated a state-of-the-art veterinary vaccine factory in Yen My II Industrial Park, Hung Yen Province, which is certified to GMP-WHO standards and produces various vaccines targeting pigs, cattle, and poultry. These expansions not only increase supply to meet global demand but also reduce production costs through economies of scale. Local manufacturing facilities ensure faster distribution and lower reliance on imports, particularly in developing countries like India.
Country Insights
The Asia Pacific Veterinary Vaccines Market is further segmented by country, with Japan holding the largest market share in 2024. The Japanese government has long recognized the importance of animal health, implementing vaccination programs for diseases such as avian influenza and Foot and Mouth Disease (FMD). The Ministry of Agriculture, Forestry, and Fisheries (MAFF) in Japan has established strict surveillance and biosecurity measures to support these vaccination efforts.
Private pharmaceutical companies in Japan also play a crucial role in developing vaccines tailored to the livestock industry's needs. For example, in 2021, Meiji Seika Pharma launched a vaccine aimed at reducing mortality rates and clinical symptoms of Swine edema disease in pigs.
Company Profiles
Key players in the Asia Pacific Veterinary Vaccines Market include Merck & Co Inc, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Zoetis Inc, Elanco Animal Health Inc, Virbac SA, Neogen Corp, Hester Biosciences Ltd, HIPRA SA, and Biovac LTD. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their product offerings and increase market share.